a Department of Urology , Tulane University School of Medicine , New Orleans , LA , USA.
b Department of Andrology , Binh Dan Hospital , Ho Chi Minh City, Vietnam.
Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):121-131. doi: 10.1080/17425255.2019.1560421. Epub 2018 Dec 22.
Erectile dysfunction (ED) is one of the most common complaints encountered by the practicing urologist, particularly when treating older men. The last 20 years have represented a pivotal time in the treatment of ED. Areas covered: Several pharmacologic agents have been approved by regulatory agencies, including phosphodiesterase type 5 (PDE5) inhibitors, intraurethral suppositories, and vasoactive injectable agents. This review will focus on the pharmacodynamic properties of these agents and the clinical consequences of those properties. Expert opinion: The decision on which agent to use should be individualized and based on the patient's goals and likelihood of success with the chosen treatment. The selection is also often driven by side-effect profiles that can be minimized by understanding the interplay between the individual patient and the medication. A thorough knowledge of the metabolism and pharmacologic properties of the available therapies will aid the urologist in selecting an individualized treatment plan for each patient.
勃起功能障碍（ED）是执业泌尿科医生最常遇到的主诉之一，尤其是在治疗老年男性时。过去 20 年是 ED 治疗的关键时期。涵盖领域：一些药物已获得监管机构的批准，包括磷酸二酯酶 5（PDE5）抑制剂、尿道内栓剂和血管活性注射剂。本文将重点介绍这些药物的药效学特性以及这些特性的临床后果。专家意见：应根据患者的目标和所选治疗的成功可能性，个体化决定使用哪种药物。选择还常常受到副作用特征的驱动，通过了解个体患者与药物之间的相互作用，可以最小化这些特征。对现有治疗方法的代谢和药理特性有透彻的了解将有助于泌尿科医生为每位患者制定个体化的治疗计划。
